A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Noble, Philip W ^a   Young, Melissa R ^a   Bernatsky, Sasha ^b   Weisbart, Richard H ^c   Hansen, James E ^a,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINUCLEAR ANTIBODY; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; CELL PENETRATING PEPTIDE; DNA; H2AFX PROTEIN, HUMAN; HISTONE;

AGONISTS; ANIMAL; CELL NUCLEUS; CELL SURVIVAL; CHEMISTRY; COLON; DEFICIENCY; DNA DAMAGE; DNA REPAIR; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HYBRIDOMA; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BRCA2 PROTEIN; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; COLON; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; HYBRIDOMAS; MICE;

EID: 84905715597     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05958     Document Type: Article

References (20)

1. Rahman, A. & Isenberg, D. A. Systemic lupus erythematosus. N. Engl. J. Med. 358, 929-939, doi:10.1056/NEJMra071297 (2008 (Pubitemid 351397092)
2. Alarcon-Segovia, D. Antinuclear antibodies: To penetrate or not to penetrate, that was the question. Lupus 10, 315-318 (2001 (Pubitemid 32520236)
3. Hansen, J. E. et al. Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Res. 67, 1769-1774, doi:10.1158/0008-5472.can-06- 3783 (2007 (Pubitemid 46383404)
4. Lawlor, M. W. et al. Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubularmyopathy. Hum. Mol. Genet. 22, 1525-1538, doi:10.1093/hmg/ddt003 (2013
5. Zhan, X. et al. Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats. Stroke 41, 538-543, doi:10.1161/ strokeaha.109.572537 (2010
6. Hansen, J. E. et al. Targeting cancer with a lupus autoantibody. Science translational medicine 4, 157ra142, doi:10.1126/scitranslmed.3004385 (2012
7. Hoeijmakers, J. H. DNA damage, aging, and cancer. N. Engl. J. Med. 361, 1475-1485, doi:10.1056/NEJMra0804615 (2009
8. Shuster, A. M. et al. DNA hydrolyzing autoantibodies. Science 256, 665-667 (1992
9. Lee, E. J. et al. Cell-penetrating autoantibody induces caspase-mediated apoptosis through catalytic hydrolysis of DNA. Bioorg. Med. Chem. 15, 2016-2023, doi:10.1016/j.bmc.2006.12.037 (2007 (Pubitemid 46188403)
10. Zack, D. J. et al. DNA mimics a self-protein that may be a target for some anti- DNA antibodies in systemic lupus erythematosus. J. Immunol. 154, 1987-1994 (1995
11. Sliwinska, M. A. et al. Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells. Mech. Ageing Dev. 130, 24-32, doi:10.1016/j.mad.2008.04.011 (2009
12. te Poele, R. H., Okorokov, A. L., Jardine, L., Cummings, J. & Joel, S. P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62, 1876-1883 (2002 (Pubitemid 34408516)
13. Achuthan, S., Santhoshkumar, T. R., Prabhakar, J., Nair, S. A.&Pillai, M. R. Druginduced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J. Biol. Chem. 286, 37813-37829, doi:10.1074/jbc.M110.200675 (2011
14. Bernatsky, S., Ramsey-Goldman, R., Foulkes, W. D., Gordon, C. & Clarke, A. E. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: A meta-analysis. Br. J. Cancer 104, 1478-1481, doi:10.1038/bjc.2011.115 (2011
15. Bernatsky, S., Ramsey-Goldman, R., Gordon, C. & Clarke, A. E. Prostate cancer in systemic lupus erythematosus. Int. J. Cancer 129, 2966-2969, doi:10.1002/ijc.25956 (2011
16. Bernatsky, S. et al. Cancer risk in systemic lupus: An updated international multicentre cohort study. J. Autoimmun. 42, 130-135, doi:10.1016/j.jaut.2012.12.009 (2013
17. Bernatsky, S. et al. Decreased breast cancer risk in systemic lupus erythematosus: The search for a genetic basis continues. Lupus 21, 896-899, doi:10.1177/0961203312443992 (2012
18. B.ernatsky, S. et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: A case-cohort study. Ann. Rheum. Dis. 67, 74-79, doi:10.1136/ard.2006.069039 (2008
19. Kostrikina, I. A., Kolesova, M. E., Orlovskaya, I. A., Buneva, V. N. & Nevinsky, G. A. Diversity of DNA-hydrolyzing antibodies from the sera of autoimmune-prone MRL/MpJ-lpr mice. J. Mol. Recognit. 24, 557-569, doi:10.1002/jmr.1067 (2011
20. Gu, L. et al. Genetic determinants of autoimmune disease and coronary vasculitis in the MRL-lpr/lpr mouse model of systemic lupus erythematosus. J. Immunol. 161, 6999-7006 (1998). (Pubitemid 28562249)